All In Biotech

Drug Trial Radar · NCT04814108

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

92

Actual

Start

Jul 28, 2021

Primary completion

Oct 22, 2025

Study completion Oct 22, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

Conditions

  • Uterine Serous Carcinoma

Interventions

  • AzenosertibDrug

    Azenosertib is an investigational drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of TEAEsTime frame: 2 years
  2. Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICRTime frame: 2 years

Locations

56 sites in 4 countries. Site status is shown where the registry gives one.

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Honor Health

    Phoenix, Arizona

  • Arizona Oncology Associates Wilmot HOPE

    Tucson, Arizona

  • Banner University Medical Center Tucson

    Tucson, Arizona

  • University of California Irvine Medical Center

    Orange, California

  • University of California San Francisco at Mission Bay

    San Francisco, California

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • University of South Florida

    Tampa, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • Northwestern University

    Evanston, Illinois

  • Maryland Oncology Hematology

    Annapolis, Maryland

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Oakland Medical Group

    Detroit, Michigan

  • Corewell Health

    Grand Rapids, Michigan

  • Revive Clinical Research

    Sterling, Michigan

  • HCA Midwest Health Kansas City Research

    Kansas City, Missouri

  • Center of Hope

    Reno, Nevada

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Optimum Clinical Research Group- Women's Oncology

    Albuquerque, New Mexico

  • Westchester Medical Center

    Hawthorne, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Oncology Hematology Care

    Cincinnati, Ohio

  • Trihealth Cancer Institute

    Cincinnati, Ohio

  • Ohio State University James Cancer Hospital

    Columbus, Ohio

  • University of Oklahoma Peggy and Charles Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Willamette Valley Cancer Institute

    Eugene, Oregon

  • Providence Portland Medical Center

    Portland, Oregon

  • Northwest Cancer Specialists

    Portland, Oregon

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Ascension St. Thomas Midtown Hospital

    Nashville, Tennessee

  • Texas Oncology Austin

    Austin, Texas

  • Texas Oncology Fort Worth Cancer Center

    Fort Worth, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology Gulf Coast

    Houston, Texas

  • Texas Oncology San Antonio

    San Antonio, Texas

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • VCU Health System

    Richmond, Virginia

  • Virginia Cancer Specialists

    Warrenton, Virginia

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.